MIR1972-1 (MicroRNA 1972-1)

miRNA-1972 is a strong prognostic marker in non-viral HCC. Dysregulation of several other miRNAs relates to pathological variables such as amount of stroma within tumor, microvascular invasion and micronodularity.

Our study highlighted the complex interplay of genetic factors in BC progression as well as the therapeutic potential of targeting specific miRNAs and their related hub genes. These findings provided novel insights into the pathogenesis of BC and suggested new direction for the therapeutic development for the cancer.

miR-1972 regulates the malignant behavior of HCC cells, especially cell proliferation, by regulating GZMH expression.

In order to elucidate the underlying interaction between matrix stiffness-mediated cell autophagy and chemoresistance, rescue experiments with rapamycin and chloroquine were conducted. Furthermore, RNA-seq results showed that miR-1972 may regulate autophagy level in response to matrix stiffness. Overall, our research shed light on the synergistic therapy of PDAC combined with gemcitabine and chloroquine, which is conducive to promoting a therapeutic effect.

Our study found miRNAs and cytokines in the peritoneal fluid of OVCA patients demonstrated different expression characteristics following CRS and HIPEC. Both changes in expression demonstrated correlations, but the role of HIPEC remains unknown, prompting the need for research in the future.

Moreover, we have found some novel significantly dysregulated miRNAs which were not reported in any previous HCC research so far. This may be due to the fact that the vast majority of research on this topic is performed on HCC of viral origin, which further emphasizes the importance of our findings.

miR-1972 contributes to the orchestration of gene-expression and physiological consequences of tamoxifen adaption.